Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | USP5 | P45974 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769922 | 0.80 | POLB (0.37) | POLBALDH1A1 | |
| SCHEMBL81624 | 0.77 | L3MBTL1 (0.39) | L3MBTL3L3MBTL1HRH3ALDH1A1PIM1 | |
| SCHEMBL12731382 | 0.76 | IRAK4 (0.36) | IRAK4PDE7AL3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL15685545 | 0.76 | IRAK4 (0.36) | IRAK4PDE7AL3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL131335 | 0.76 | IRAK4 (0.36) | IRAK4PDE7AL3MBTL3L3MBTL1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL153021 | 0.75 | IRAK4 (0.36) | IRAK4PDE7AL3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL4771257 | 0.74 | ADH1B (0.52) | IRAK4PDE7AL3MBTL3L3MBTL1SIGMAR1 | |
| SCHEMBL3226408 | 0.73 | POLB (0.44) | PDE7AL3MBTL3L3MBTL1SIGMAR1POLB | |
| SCHEMBL12793041 | 0.73 | POLB (0.44) | PDE7AL3MBTL3L3MBTL1SIGMAR1POLB | |
| SCHEMBL1936070 | 0.73 | KDM4E (0.45) | PDE7AL3MBTL3L3MBTL1SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | IRAK4 435/4885PDE7A 4128/4885L3MBTL3 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.